Does the media favor CRNX or TRVI?

In the previous week, Crinetics Pharmaceuticals had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 10 mentions for Crinetics Pharmaceuticals and 9 mentions for Trevi Therapeutics. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Trevi Therapeutics' score of 1.22 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 8 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Trevi Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TRVI or LNTH?

In the previous week, Lantheus had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 10 mentions for Lantheus and 9 mentions for Trevi Therapeutics. Lantheus' average media sentiment score of 1.33 beat Trevi Therapeutics' score of 1.22 indicating that Lantheus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TRVI or LQDA?

In the previous week, Trevi Therapeutics had 2 more articles in the media than Liquidia. MarketBeat recorded 9 mentions for Trevi Therapeutics and 7 mentions for Liquidia. Trevi Therapeutics' average media sentiment score of 1.22 beat Liquidia's score of 0.86 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Liquidia 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, BLTE or TRVI?

Belite Bio is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A

Is BLTE or TRVI more profitable?

Belite Bio's return on equity of -11.84% beat Trevi Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% Trevi Therapeutics N/A -23.59% -22.64%

Does the media refer more to BLTE or TRVI?

In the previous week, Trevi Therapeutics had 7 more articles in the media than Belite Bio. MarketBeat recorded 9 mentions for Trevi Therapeutics and 2 mentions for Belite Bio. Trevi Therapeutics' average media sentiment score of 1.22 beat Belite Bio's score of 0.93 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Trevi Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, TRVI or DFTX?

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trevi Therapeutics N/A N/A -$42.76M -$0.34 N/A Definium Therapeutics N/A N/A -$183.79M -$3.43 N/A

Is TRVI or DFTX more profitable?

Trevi Therapeutics' return on equity of -23.59% beat Definium Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trevi Therapeutics N/A -23.59% -22.64% Definium Therapeutics N/A -84.01% -63.66%

Does the media prefer TRVI or DFTX?

In the previous week, Trevi Therapeutics had 4 more articles in the media than Definium Therapeutics. MarketBeat recorded 9 mentions for Trevi Therapeutics and 5 mentions for Definium Therapeutics. Trevi Therapeutics' average media sentiment score of 1.22 beat Definium Therapeutics' score of 0.91 indicating that Trevi Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trevi Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Definium Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Trevi Therapeutics (TRVI) Competitors

$16.79 -1.17 (-6.51%)

As of 08/28/2026 04:00 PM Eastern

Compare

TRVI vs. CRNX, LNTH, LQDA, BLTE, and DFTX

Should you buy Trevi Therapeutics stock or one of its competitors? Trevi Therapeutics's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Lantheus (LNTH), Liquidia (LQDA), Belite Bio (BLTE), and Definium Therapeutics (DFTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Trevi Therapeutics compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Trevi Therapeutics (NASDAQ:TRVI) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

Trevi Therapeutics has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Trevi Therapeutics' return on equity of -23.59% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Crinetics Pharmaceuticals has a beta of 0.12, meaning that its stock price is 88% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

In the previous week, Crinetics Pharmaceuticals had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 10 mentions for Crinetics Pharmaceuticals and 9 mentions for Trevi Therapeutics. Crinetics Pharmaceuticals' average media sentiment score of 1.56 beat Trevi Therapeutics' score of 1.22 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crinetics Pharmaceuticals	8 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Trevi Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Comparatively, 15.4% of Trevi Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Trevi Therapeutics has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$42.16M	213.46	-$465.32M	-$5.04	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

Crinetics Pharmaceuticals currently has a consensus target price of $81.00, suggesting a potential downside of 4.53%. Trevi Therapeutics has a consensus target price of $27.08, suggesting a potential upside of 61.31%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Trevi Therapeutics beats Crinetics Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Lantheus?

Trevi Therapeutics (NASDAQ:TRVI) and Lantheus (NASDAQ:LNTH) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability, institutional ownership and media sentiment.

Lantheus has higher revenue and earnings than Trevi Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Lantheus	$1.54B	4.27	$233.56M	$4.14	24.34

Trevi Therapeutics presently has a consensus price target of $27.08, indicating a potential upside of 61.31%. Lantheus has a consensus price target of $108.11, indicating a potential upside of 7.29%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Trevi Therapeutics is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29

Lantheus has a net margin of 17.69% compared to Trevi Therapeutics' net margin of 0.00%. Lantheus' return on equity of 28.10% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Lantheus	17.69%	28.10%	14.35%

Trevi Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market.

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 99.1% of Lantheus shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 1.7% of Lantheus shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Lantheus had 1 more articles in the media than Trevi Therapeutics. MarketBeat recorded 10 mentions for Lantheus and 9 mentions for Trevi Therapeutics. Lantheus' average media sentiment score of 1.33 beat Trevi Therapeutics' score of 1.22 indicating that Lantheus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lantheus beats Trevi Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Liquidia?

Trevi Therapeutics (NASDAQ:TRVI) and Liquidia (NASDAQ:LQDA) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

Trevi Therapeutics has higher earnings, but lower revenue than Liquidia. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Liquidia	$450.91M	13.44	-$68.92M	$1.37	49.41

Trevi Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Liquidia has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

Liquidia has a net margin of 30.74% compared to Trevi Therapeutics' net margin of 0.00%. Liquidia's return on equity of 149.65% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Liquidia	30.74%	149.65%	36.30%

Trevi Therapeutics currently has a consensus price target of $27.08, suggesting a potential upside of 61.31%. Liquidia has a consensus price target of $98.08, suggesting a potential upside of 44.90%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Trevi Therapeutics is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45

In the previous week, Trevi Therapeutics had 2 more articles in the media than Liquidia. MarketBeat recorded 9 mentions for Trevi Therapeutics and 7 mentions for Liquidia. Trevi Therapeutics' average media sentiment score of 1.22 beat Liquidia's score of 0.86 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Liquidia	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 15.4% of Trevi Therapeutics shares are held by insiders. Comparatively, 25.6% of Liquidia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Trevi Therapeutics beats Liquidia on 9 of the 16 factors compared between the two stocks.

How does Trevi Therapeutics compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Trevi Therapeutics (NASDAQ:TRVI) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

In the previous week, Trevi Therapeutics had 7 more articles in the media than Belite Bio. MarketBeat recorded 9 mentions for Trevi Therapeutics and 2 mentions for Belite Bio. Trevi Therapeutics' average media sentiment score of 1.22 beat Belite Bio's score of 0.93 indicating that Trevi Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Trevi Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Belite Bio is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A

0.5% of Belite Bio shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 13.3% of Belite Bio shares are held by insiders. Comparatively, 15.4% of Trevi Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Belite Bio's return on equity of -11.84% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Trevi Therapeutics	N/A	-23.59%	-22.64%

Belite Bio has a beta of -1.22, suggesting that its share price is 222% less volatile than the broader market. Comparatively, Trevi Therapeutics has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Belite Bio currently has a consensus target price of $205.80, indicating a potential upside of 35.64%. Trevi Therapeutics has a consensus target price of $27.08, indicating a potential upside of 61.31%. Given Trevi Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Trevi Therapeutics is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Trevi Therapeutics beats Belite Bio on 12 of the 14 factors compared between the two stocks.

How does Trevi Therapeutics compare to Definium Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Definium Therapeutics (NASDAQ:DFTX) are both mid-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Trevi Therapeutics is trading at a lower price-to-earnings ratio than Definium Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.34	N/A
Definium Therapeutics	N/A	N/A	-$183.79M	-$3.43	N/A

Trevi Therapeutics currently has a consensus price target of $27.08, suggesting a potential upside of 61.31%. Definium Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 53.73%. Given Trevi Therapeutics' higher probable upside, analysts clearly believe Trevi Therapeutics is more favorable than Definium Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Definium Therapeutics	1 Sell rating(s)	0 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	3.00

Trevi Therapeutics' return on equity of -23.59% beat Definium Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-23.59%	-22.64%
Definium Therapeutics	N/A	-84.01%	-63.66%

In the previous week, Trevi Therapeutics had 4 more articles in the media than Definium Therapeutics. MarketBeat recorded 9 mentions for Trevi Therapeutics and 5 mentions for Definium Therapeutics. Trevi Therapeutics' average media sentiment score of 1.22 beat Definium Therapeutics' score of 0.91 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trevi Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Definium Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.8% of Trevi Therapeutics shares are owned by institutional investors. Comparatively, 27.9% of Definium Therapeutics shares are owned by institutional investors. 15.4% of Trevi Therapeutics shares are owned by insiders. Comparatively, 2.4% of Definium Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Trevi Therapeutics has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market. Comparatively, Definium Therapeutics has a beta of 2.23, indicating that its stock price is 123% more volatile than the broader market.

Summary

Trevi Therapeutics beats Definium Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Trevi Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TRVI vs. The Competition

Export

Metric	Trevi Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.39B	$12.15B	$7.20B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-49.38	787.65	273.16	25.45
Price / Sales	N/A	789.00	640.19	89.89
Price / Cash	N/A	91.95	76.74	53.00
Price / Book	7.43	11.97	12.98	6.14
Net Income	-$42.76M	$2.83B	$3.48B	$348.86M
7 Day Performance	-6.51%	0.39%	0.13%	-0.80%
1 Month Performance	-8.75%	5.34%	7.08%	4.13%
1 Year Performance	131.27%	6.05%	24.67%	15.17%

Trevi Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TRVI Trevi Therapeutics	3.4546 of 5 stars	$16.79 -6.5%	$27.08 +61.3%	+131.3%	$2.39B	N/A	N/A	20	News Coverage Positive News
CRNX Crinetics Pharmaceuticals	1.6588 of 5 stars	$84.85 0.0%	$81.00 -4.5%	+173.8%	$9.00B	$7.70M	N/A	210	Positive News
LNTH Lantheus	3.9474 of 5 stars	$100.96 +0.1%	$108.11 +7.1%	+83.6%	$6.59B	$1.56B	24.39	1,193	Positive News Analyst Upgrade
LQDA Liquidia	4.1909 of 5 stars	$71.65 +1.6%	$98.08 +36.9%	+144.5%	$6.41B	$158.32M	52.30	50	Insider Trade
BLTE Belite Bio	3.1481 of 5 stars	$157.79 -2.4%	$205.80 +30.4%	+140.7%	$6.33B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TRVI) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trevi Therapeutics (TRVI) Competitors

TRVI vs. CRNX, LNTH, LQDA, BLTE, and DFTX

How does Trevi Therapeutics compare to Crinetics Pharmaceuticals?

Summary

How does Trevi Therapeutics compare to Lantheus?

Summary

How does Trevi Therapeutics compare to Liquidia?

Summary

How does Trevi Therapeutics compare to Belite Bio?

Summary

How does Trevi Therapeutics compare to Definium Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Trevi Therapeutics (TRVI) Competitors

TRVI vs. CRNX, LNTH, LQDA, BLTE, and DFTX

How does Trevi Therapeutics compare to Crinetics Pharmaceuticals?

Is CRNX or TRVI more profitable?

Which has more volatility & risk, CRNX or TRVI?

Does the media favor CRNX or TRVI?

Do insiders & institutionals hold more shares of CRNX or TRVI?

Which has preferable valuation and earnings, CRNX or TRVI?

Do analysts rate CRNX or TRVI?

Summary

How does Trevi Therapeutics compare to Lantheus?

Which has better valuation and earnings, TRVI or LNTH?

Do analysts rate TRVI or LNTH?

Is TRVI or LNTH more profitable?

Which has more volatility and risk, TRVI or LNTH?

Do insiders and institutionals hold more shares of TRVI or LNTH?

Does the media refer more to TRVI or LNTH?

Summary

How does Trevi Therapeutics compare to Liquidia?

Which has better earnings & valuation, TRVI or LQDA?

Which has more volatility & risk, TRVI or LQDA?

Is TRVI or LQDA more profitable?

Do analysts rate TRVI or LQDA?

Does the media prefer TRVI or LQDA?

Do insiders & institutionals have more ownership in TRVI or LQDA?

Summary

How does Trevi Therapeutics compare to Belite Bio?

Does the media refer more to BLTE or TRVI?

Which has stronger earnings & valuation, BLTE or TRVI?

Do institutionals and insiders believe in BLTE or TRVI?

Is BLTE or TRVI more profitable?

Which has more risk and volatility, BLTE or TRVI?

Do analysts recommend BLTE or TRVI?

Summary

How does Trevi Therapeutics compare to Definium Therapeutics?

Which has stronger earnings and valuation, TRVI or DFTX?

Do analysts rate TRVI or DFTX?

Is TRVI or DFTX more profitable?

Does the media prefer TRVI or DFTX?

Do institutionals and insiders hold more shares of TRVI or DFTX?

Which has more risk & volatility, TRVI or DFTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRVI vs. The Competition

Trevi Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools